サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1571896

血液腫瘍検査の世界市場

Hemato Oncology Testing

出版日
ページ情報
英文 92 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
血液腫瘍検査の世界市場
出版日: 2024年10月18日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 92 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血液腫瘍検査の世界市場は2030年までに米国で142億米ドルに達する見込み

2023年に49億米ドルと推定される血液腫瘍検査の世界市場は、2030年には142億米ドルに達し、分析期間2023-2030年のCAGRは16.3％で成長すると予測されます。血液腫瘍検査本レポートで分析したセグメントの1つである血液腫瘍検査サービスは、CAGR 15.4％を記録し、分析期間終了時には86億米ドルに達すると予測されます。血液腫瘍測定キット分野の成長率は、分析期間中CAGR 17.7%と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 20.7％で成長予測

米国の血液腫瘍検査市場は2023年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに36億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは20.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.5％と13.7％と予測されています。欧州では、ドイツがCAGR約12.6%で成長すると予測されています。

世界の血液腫瘍検査市場- 主要動向と促進要因のまとめ

血液腫瘍検査はがん診断をどう変えるか？

白血病、リンパ腫、骨髄腫などの血液がんの診断に特化した血液腫瘍検査は、現代のがん診断の要となっています。これらの検査には、分子診断学、細胞遺伝学、フローサイトメトリーなどが含まれ、がん細胞、遺伝子変異、その他のバイオマーカーを同定し、早期発見や標的治療の選択に役立てています。血液がんの罹患率の増加と個別化医療の台頭が、血液腫瘍検査の需要を大きく押し上げています。この市場は、がんの診断だけでなく、病気の進行のモニタリングや治療効果の評価にも不可欠であり、臨床医に患者管理に関する貴重な洞察を提供しています。

技術の進歩はどのように血液腫瘍検査を形成しているか？

分子診断、次世代シーケンシング（NGS）、リキッドバイオプシー技術における技術の進歩が血液腫瘍検査に革命をもたらしました。NGSは包括的なゲノム・プロファイリングを可能にし、特定の治療法の標的となりうる変異の同定を支援し、それによってプレシジョン・オンコロジーの分野を前進させる。血流中の循環腫瘍DNAを解析するリキッドバイオプシーは、従来の組織生検に代わる低侵襲の代替法を提供し、より早期の診断とがんの進行の継続的なモニタリングを可能にします。データ解析におけるAIとバイオインフォマティクス・ツールの統合は、検査結果の精度をさらに高め、より迅速で正確な診断を可能にしています。これらの技術革新は、より個別化された治療計画への道を開き、血液腫瘍学における患者の転帰を改善しています。

セグメントと用途は血液腫瘍検査市場をどのように定義しているか？

検査の種類には分子検査、フローサイトメトリー、免疫組織化学などがあり、特定の遺伝子変異を検出できる分子検査が最大のシェアを占めています。ポリメラーゼ連鎖反応（PCR）や次世代シーケンシング（NGS）などの治療技術が市場を独占しており、がん細胞の詳細な分析を可能にし、個別化治療のための重要な情報を提供しています。血液腫瘍検査のアプリケーションには、診断、予後予測、治療モニタリングが含まれるが、生存率の向上には早期発見が不可欠であるため、診断検査が最も重要な用途です。市場を牽引しているのは病院、診断研究所、研究機関であり、病院は高度な検査技術を利用できることから最大のエンドユーザーとなっています。

血液腫瘍検査市場の成長を促進する要因は？

血液腫瘍検査市場の成長は、血液がんの有病率の増加、分子診断学の進歩、個別化医療の台頭など、いくつかの要因によってもたらされます。早期かつ正確ながん検出に対する需要の高まりは、分子検査やNGS技術の幅広い導入につながっています。がん診断の改善を目的とした政府の取り組みや、がん研究への資金提供の増加も、市場成長に大きく寄与しています。さらに、標的療法や免疫療法の開発により、特定のバイオマーカーや変異を特定するための高度な診断検査の必要性が高まっています。新興市場における診断能力の拡大や、リキッドバイオプシーなどの低侵襲検査法への注目の高まりも、市場成長のさらなる促進要因となっています。

調査対象企業の例（注目の36社）

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Archerdx, Inc.
  • Arup Laboratories, Inc.
  • Asuragen, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Molecularmd（Subsidiary of Icon PLC）
  • Qiagen N.V.
  • Sanofi SA
  • Thermo Fisher Scientific, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP21944

Global Hemato Oncology Testing Market to Reach US$14.2 Billion by 2030

The global market for Hemato Oncology Testing estimated at US$4.9 Billion in the year 2023, is expected to reach US$14.2 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2023-2030. Hemato Oncology Testing Services, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the Hemato Oncology Assay Kits segment is estimated at 17.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 20.7% CAGR

The Hemato Oncology Testing market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 20.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.5% and 13.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global Hemato Oncology Testing Market - Key Trends and Drivers Summarized

How Is Hemato Oncology Testing Transforming Cancer Diagnosis?

Hemato oncology testing, which focuses on diagnosing blood cancers such as leukemia, lymphoma, and myeloma, has become a cornerstone of modern cancer diagnostics. These tests include molecular diagnostics, cytogenetics, and flow cytometry to identify cancerous cells, genetic mutations, and other biomarkers that aid in early detection and targeted therapy selection. The increasing incidence of blood cancers, coupled with the rise in personalized medicine, has significantly driven demand for hemato oncology testing. This market is essential not only for diagnosing cancer but also for monitoring disease progression and assessing treatment efficacy, offering clinicians valuable insights into patient management.

How Are Technological Advancements Shaping Hemato Oncology Testing?

Technological advancements in molecular diagnostics, next-generation sequencing (NGS), and liquid biopsy techniques have revolutionized hemato oncology testing. NGS allows for comprehensive genomic profiling, helping identify mutations that may be targeted by specific therapies, thereby advancing the field of precision oncology. Liquid biopsies, which analyze circulating tumor DNA in the bloodstream, offer a minimally invasive alternative to traditional tissue biopsies, enabling earlier diagnosis and continuous monitoring of cancer progression. The integration of AI and bioinformatics tools in data analysis has further enhanced the accuracy of test results, allowing for quicker and more precise diagnoses. These innovations are paving the way for more personalized treatment plans, improving patient outcomes in hemato oncology.

How Are Segments and Applications Defining the Hemato Oncology Testing Market?

Test types include molecular tests, flow cytometry, and immunohistochemistry, with molecular tests holding the largest share due to their ability to detect specific genetic mutations. Technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) dominate the market, enabling detailed analysis of cancerous cells and providing crucial information for personalized treatment. Applications of hemato oncology testing include diagnosis, prognosis, and treatment monitoring, with diagnostic testing being the most significant application as early detection remains critical in improving survival rates. The market is driven by hospitals, diagnostic laboratories, and research institutions, with hospitals being the largest end-users due to their access to advanced testing technologies.

What Factors Are Driving the Growth in the Hemato Oncology Testing Market?

The growth in the hemato oncology testing market is driven by several factors, including the increasing prevalence of blood cancers, advancements in molecular diagnostics, and the rise of personalized medicine. The growing demand for early and accurate cancer detection has led to wider adoption of molecular tests and NGS technologies. Government initiatives aimed at improving cancer diagnostics, along with increased funding for cancer research, are also significant contributors to market growth. Furthermore, the development of targeted therapies and immunotherapies has heightened the need for advanced diagnostic tests to identify specific biomarkers and mutations. The expansion of diagnostic capabilities in emerging markets and the growing focus on minimally invasive testing methods, such as liquid biopsies, are additional drivers of market growth.

Select Competitors (Total 36 Featured) -

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Archerdx, Inc.
  • Arup Laboratories, Inc.
  • Asuragen, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Molecularmd (Subsidiary of Icon PLC)
  • Qiagen N.V.
  • Sanofi SA
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Hemato Oncology Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Hematologic Cancers Drives Demand for Hemato Oncology Testing
    • Technological Advancements in Molecular Diagnostics Strengthen Growth of Hemato Oncology Testing Market
    • Increasing Focus on Personalized Medicine Expands Addressable Market for Precision Oncology Testing
    • Growing Adoption of Next-Generation Sequencing (NGS) in Hemato Oncology Testing Spurs Market Innovation
    • Rising Availability of Liquid Biopsy Solutions Generates Demand for Non-Invasive Cancer Testing
    • Expansion of Companion Diagnostics in Hemato Oncology Strengthens Business Case for Testing Solutions
    • Rising Focus on Early Cancer Detection and Screening Expands Hemato Oncology Testing Market
    • Growth in Targeted Cancer Therapies Drives Demand for Comprehensive Genetic Testing
    • Surge in Adoption of Immuno-Oncology Therapies Spurs Need for Advanced Testing Solutions
    • Rising Awareness and Accessibility of Cancer Testing in Emerging Markets Expands Market Opportunities
    • Growing Use of Artificial Intelligence and Machine Learning in Cancer Testing Accelerates Innovation
    • Regulatory Push for Precision Medicine in Oncology Strengthens Adoption of Hemato Oncology Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Hemato Oncology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Assay Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for IHC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for IHC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for IHC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for NGS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cytogenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Hemato Oncology Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hodgkin Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hodgkin Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hodgkin Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • JAPAN
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • CHINA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • EUROPE
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Hemato Oncology Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • FRANCE
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • GERMANY
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Hemato Oncology Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • INDIA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Hemato Oncology Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Hemato Oncology Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • AFRICA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030

IV. COMPETITION